Arbutus Biopharma (ABUS) EBT Margin (2013 - 2026)
Arbutus Biopharma (ABUS) posted quarterly EBT Margin of 94.74% for Q1 2026, up 148533.0% year-on-year from N/an in Q1 2025, and up 120.04% on a QoQ basis from 472.69% in Q4 2025.
Arbutus Biopharma (ABUS) EBT Margin (2013 - 2026) Analysis & Trends
Arbutus Biopharma (ABUS) has reported EBT Margin for 14 consecutive years, with 94.74% the latest figure, recorded in Q1 2026.
- Quarterly EBT Margin rose 148533.0% year-over-year to 94.74% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 83.32% (up 127966.0% YoY) and the FY2025 annual result came in at 1530.09%, down 39704.0% from the prior year.
- EBT Margin improved to 94.74% in Q1 2026 per ABUS's latest filing, from 472.69% in the prior quarter.
- Over the last five years, EBT Margin for ABUS reached as high as 94.74% in Q1 2026 and fell as low as 1472.89% in Q3 2024.
- A 5-year average of 622.2% and a median of 431.6% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin plunged 104129 bps — and 2026, when it soared 148533 bps.
- Year by year, EBT Margin stood at 351.19% in 2022, then plunged by 156 bps to 900.33% in 2023, then grew by 12 bps to 794.09% in 2024, then surged by 40 bps to 472.69% in 2025, then jumped by 120 bps to 94.74% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 94.74%, 472.69%, and 1461.25% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arbutus Biopharma | 880.36 Mn | 785.13 Mn | - | 94.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94.74% |
| Dec 31, 2025 | -472.69% |
| Sep 30, 2025 | -1,461.25% |
| Jun 30, 2025 | 23.30% |
| Mar 31, 2025 | -1,390.59% |
| Dec 31, 2024 | -794.09% |
| Sep 30, 2024 | -1,472.89% |
| Jun 30, 2024 | -1,150.12% |
| Mar 31, 2024 | -1,174.02% |
| Dec 31, 2023 | -900.33% |
| Sep 30, 2023 | -431.60% |
| Jun 30, 2023 | -367.53% |
| Mar 31, 2023 | -244.34% |
| Dec 31, 2022 | -351.19% |
| Sep 30, 2022 | -295.14% |
| Jun 30, 2022 | -99.66% |
| Mar 31, 2022 | -89.98% |
| Dec 31, 2021 | -665.03% |
| Sep 30, 2021 | -573.59% |
| Jun 30, 2021 | -832.42% |